

ASX ANNOUNCEMENT: June 1, 2017

NASDAQ on Hold Pending NASH Interim Analysis Results

- Interim NASH Clinical Trial Results expected during first week of July 2017
- Current NASDAQ Pricing offer not acceptable for shareholders
- Brokers advise pricing unattractive due to pending interim analysis inflection point

For personal use only

NASDAQ on Hold Pending NASH Interim Analysis Results

Melbourne, Australia, June 1, 2017: Australian biopharmaceutical Company, Immuron Limited (ASX: IMC), today announces that the Company has decided to place its NASDAQ listing efforts on hold for the time being pending release of the interim analysis results of the Company's Phase II NASH Clinical Trial anticipated to be released by the first week of July 2017.

Immuron Chairman Dr Roger Aston commented;

"The current pricing being offered by potential investors for our NASDAQ listing was just not acceptable to the Board and would have meant a heavy discount for all existing shareholders which the Board was not willing to accept. Our US brokers have advised us that the primary reason for the low pricing offers was due to the fact we're so close to a major inflection point with the pending release of our NASH clinical trial interim analysis.

We have made a significant time and cost investment in the NASDAQ process to get to this point, and we hope to be able to progress this through to a NASDAQ listing following the release of the NASH interim analysis by the end of the first week of July 2017."

-- END --

COMPANY CONTACT:

Thomas Liquard
Chief Executive Officer
Ph: +61 (0)3 9824 5254
thomasliquard@immuron.com

IMMURON INVESTOR RELATIONS:

Peter Taylor
NWR Communications
Ph: +61 (0)4 1203 6231
peter@nwrcommunications.com.au

ABOUT IMMURON:

Immuron Ltd (ASX: IMC) is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers' diarrhea whilst its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH. These products together with the Company's other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market. For more information visit: <http://www.immuron.com>

FORWARD-LOOKING STATEMENTS:

Certain statements made in this release are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron

will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

For personal use only